Phagelux Raises Series B for Bacteriophage-Based Agri-Biotech Solutions

Phagelux Secures Series B Funding

Phagelux (菲吉乐科), a Chinese agri-biotech company specializing in bacteriophage- and lysin-based biological alternatives to antibiotics and chemical pesticides, has raised a Series B funding round. The investment was announced on August 31, 2026, with the amount undisclosed and denominated in CNY.

Company Overview

Founded by American entrepreneur Mark Engel in the early 2010s with incubation from Fosun Pharma, Phagelux is headquartered in Wuxi, Jiangsu. The company operates research and development labs and manufacturing facilities in both China and North America. It maintains one of the largest commercial agricultural phage libraries and holds bio-pesticide registrations in Chinese and overseas markets.

Phagelux's product lines span crop science, animal health, food safety, and feed additives, offering biological alternatives to traditional antibiotics and chemical pesticides.

Funding Details

The Series B round was announced on August 31, 2026. The specific funding amount was not disclosed, and no lead investor or additional investors were listed in the announcement.

Implications

This funding will support Phagelux's continued development and commercialization of its phage-based solutions, addressing the growing demand for sustainable agricultural practices. The company's extensive phage library and regulatory approvals position it well in the agri-biotech sector.

For more information, visit Phagelux's website.